Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been given a consensus rating of “Moderate Buy” by the twenty-four analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, twenty have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $125.6522.

Several research firms have recently issued reports on KYMR. Citigroup reiterated a “buy” rating on shares of Kymera Therapeutics in a report on Thursday, August 6th. Canaccord Genuity Group upped their target price on Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research report on Friday, June 26th. Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. B. Riley Financial increased their price target on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Royal Bank Of Canada cut Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and lifted their price target for the company from $106.00 to $115.00 in a research report on Monday, July 13th.

Insider Transactions at Kymera Therapeutics

In related news, CEO Nello Mainolfi sold 80,000 shares of Kymera Therapeutics stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total transaction of $9,223,200.00. Following the transaction, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at $76,848,624.72. The trade was a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the completion of the sale, the director owned 240,123 shares in the company, valued at approximately $25,573,099.50. This trade represents a 86.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 3,587,629 shares of company stock worth $386,183,782. Corporate insiders own 15.98% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after acquiring an additional 98 shares in the last quarter. US Bancorp DE grew its position in Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after acquiring an additional 166 shares in the last quarter. Proficio Capital Partners LLC increased its stake in shares of Kymera Therapeutics by 1.8% during the 2nd quarter. Proficio Capital Partners LLC now owns 11,045 shares of the company’s stock worth $1,267,000 after purchasing an additional 200 shares during the last quarter. Glenmede Trust Co. NA increased its stake in shares of Kymera Therapeutics by 3.6% during the 1st quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock worth $565,000 after purchasing an additional 235 shares during the last quarter. Finally, Cetera Investment Advisers increased its stake in shares of Kymera Therapeutics by 7.5% during the 1st quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock worth $300,000 after purchasing an additional 252 shares during the last quarter.

Kymera Therapeutics Stock Up 4.6%

Shares of NASDAQ KYMR opened at $126.64 on Friday. The stock has a market cap of $10.53 billion, a P/E ratio of -39.09 and a beta of 1.95. The firm’s 50-day simple moving average is $110.92 and its 200 day simple moving average is $92.80. Kymera Therapeutics has a fifty-two week low of $39.84 and a fifty-two week high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. During the same quarter in the prior year, the firm posted ($0.95) EPS. Kymera Therapeutics’s revenue was up 465.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Kymera Therapeutics will post -3.75 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.